[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Barber et al., 1994 - Google Patents

A pharmacological profile of the novel, peripherally‐selective k‐opioid receptor agonist, EMD 61753

Barber et al., 1994

View PDF
Document ID
14904236447195896480
Author
Barber A
Bartoszyk G
Bender H
Gottschlich R
Greiner H
Harting J
Mauler F
Minck K
Murray R
Simon M
Seyfried C
Publication year
Publication venue
British journal of pharmacology

External Links

Snippet

1 The pharmacological properties of the novel diarylacetamide k‐opioid receptor agonist, EMD 61753, have been compared with those of ICI 197067 (a centrally‐acting k agonist) and ICI204448 (a peripherally‐selective k agonist). 2 EMD 61753 binds with high affinity …
Continue reading at bpspubs.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application

Similar Documents

Publication Publication Date Title
Barber et al. A pharmacological profile of the novel, peripherally‐selective k‐opioid receptor agonist, EMD 61753
Rasmussen et al. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal
Kreek et al. Pharmacotherapy of addictions
Fainsinger et al. Methadone in the management of cancer pain: a review
Popik et al. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine
Fu et al. Nicotine-induced norepinephrine release in the rat amygdala and hippocampus is mediated through brainstem nicotinic cholinergic receptors
Popik et al. Pharmacology of ibogaine and ibogaine-related alkaloids
Charney et al. α2Adrenergic and Opiate Receptor Blockade: Synergistic Effects on Anxiety in Healthy Subjects
JP2002522383A (en) Treatment of addiction or addiction-related behavior
CA2942638A1 (en) Method for noribogaine treatment of addiction in patients on methadone
Massingham et al. The role of presynaptic receptors in the cardiovascular actions of N, N-di-n-propyldopamine in the cat and dog
Miller Inhibition of ADH release in the rat by narcotic antagonists
Agabio et al. The development of medications for alcohol-use disorders targeting the GABAB receptor system
Miele et al. On the mechanism of d‐amphetamine‐induced changes in glutamate, ascorbic acid and uric acid release in the striatum of freely moving rats
Buccafusco Cardiovascular changes during morphine withdrawal in the rat: effects of clonidine
Zhou et al. Preclinical studies on nalfurafine (TRK-820), a clinically used KOR agonist
Barjavel et al. Relationship between morphine analgesia and cortical extracellular fluid levels of morphine and its metabolites in the rat: a microdialysis study
Bristow et al. Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats
Barber et al. Central and peripheral actions of the novel κ‐opioid receptor agonist, EMD 60400
Matsui et al. Activation of µ‐opioid receptors and block of KIR3 potassium channels and NMDA receptor conductance by l‐and d‐methadone in rat locus coeruleus
Choi et al. Antinociceptive profiles of platycodin D in the mouse
Bellissant et al. Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers.
Sullivan et al. Suppression of acute and chronic opioid withdrawal by a selective soluble guanylyl cyclase inhibitor
Wang et al. Neurotransmitter modulation of VIP release from cat cerebral cortex
Nascimento et al. I1-imidazoline receptor-mediated cardiovascular and metabolic effects in high-fat diet-induced metabolic syndrome in rats